Janney Montgomery Scott LLC Has $2.01 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

Janney Montgomery Scott LLC lowered its position in Hologic, Inc. (NASDAQ:HOLX) by 5.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,843 shares of the medical equipment provider’s stock after selling 1,478 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Hologic were worth $2,007,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Benson Investment Management Company Inc. acquired a new stake in shares of Hologic in the fourth quarter valued at approximately $4,832,000. Clean Yield Group boosted its holdings in shares of Hologic by 18.9% during the 4th quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock worth $3,291,000 after buying an additional 7,266 shares during the period. GAMMA Investing LLC grew its stake in Hologic by 17.9% in the 3rd quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock valued at $312,000 after buying an additional 582 shares during the last quarter. Janus Henderson Group PLC lifted its position in Hologic by 2.9% during the third quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock worth $2,344,000 after acquiring an additional 800 shares during the last quarter. Finally, Versor Investments LP bought a new stake in shares of Hologic during the third quarter worth approximately $1,677,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Down 0.0 %

HOLX stock opened at $72.14 on Monday. Hologic, Inc. has a 1-year low of $68.61 and a 1-year high of $84.67. The stock has a market cap of $16.28 billion, a price-to-earnings ratio of 21.66, a price-to-earnings-growth ratio of 2.33 and a beta of 0.97. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The company’s 50 day moving average is $73.35 and its 200 day moving average is $78.07.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. The company had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.89 earnings per share. Sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.88% of the stock is currently owned by insiders.

Analysts Set New Price Targets

HOLX has been the topic of a number of analyst reports. Leerink Partners lowered their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Needham & Company LLC reissued a “buy” rating and set a $90.00 price target on shares of Hologic in a research note on Monday, January 13th. BNP Paribas upgraded Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Finally, Royal Bank of Canada upped their target price on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Seven investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $88.92.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.